Back to Search
Start Over
Future directions for gemcitabine in the treatment of genitourinary cancer.
- Source :
-
Seminars in oncology [Semin Oncol] 2002 Feb; Vol. 29 (1 Suppl 3), pp. 40-5. - Publication Year :
- 2002
-
Abstract
- Because of an annual morbidity of 225,000 patients and mortality of over 56,000 patients per year in the United States from metastatic genitourinary malignancies, there is a great need for new systemic agents. With its activity and low toxicity, gemcitabine has begun to play a growing role in genitourinary cancer treatment and clinical trials. Substantial activity has been reported for gemcitabine combinations in the treatment of bladder cancer (median survival in one study of nearly 20 months) and for gemcitabine alone or in combinations in testicular cancer patients. Lower (but real) levels of activity have also been observed for gemcitabine combinations in renal carcinoma (17% response rate) and for monotherapy in hormone-refractory prostate cancer (7%). These data suggest the need for further trials of gemcitabine alone or in combinations in genitourinary cancer patients.<br /> (Copyright 2002, Elsevier Science (USA). All rights reserved.)
- Subjects :
- Female
Forecasting
Humans
Kidney Neoplasms diagnosis
Kidney Neoplasms drug therapy
Kidney Neoplasms mortality
Male
Morbidity
Prostatic Neoplasms diagnosis
Prostatic Neoplasms drug therapy
Prostatic Neoplasms mortality
Survival Analysis
Testicular Neoplasms diagnosis
Testicular Neoplasms drug therapy
Testicular Neoplasms mortality
Treatment Outcome
United States epidemiology
Urinary Bladder Neoplasms diagnosis
Urinary Bladder Neoplasms drug therapy
Urinary Bladder Neoplasms mortality
Urogenital Neoplasms diagnosis
Urogenital Neoplasms mortality
Gemcitabine
Antimetabolites, Antineoplastic therapeutic use
Deoxycytidine analogs & derivatives
Deoxycytidine therapeutic use
Urogenital Neoplasms drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 0093-7754
- Volume :
- 29
- Issue :
- 1 Suppl 3
- Database :
- MEDLINE
- Journal :
- Seminars in oncology
- Publication Type :
- Academic Journal
- Accession number :
- 11894007
- Full Text :
- https://doi.org/10.1053/sonc.2002.30755